- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03922906
Evaluation of Bowel Cleansing Using the Pure-Vu System in Patients With History of Inadequate Bowel Preparation
Study Overview
Detailed Description
The study is planned as a single arm, open trial will include up to 30 patients, aim to evaluate the performance of Pure-Vu System in cleansing patients' colon with history of inadequate bowel preparation who are indicated for a colonoscopy procedure.
Subjects will be enrolled at up to 3 clinical sites in Israel. Subjects who meet the eligibility criteria will be required to follow a standard bowel preparation instruction. Patients will be asked to record and provide their diet and bowel movements in the provided diary log at time of their scheduled colonoscopy (Diary log is provided in appendix C) and to complete a satisfaction questionnaire include feedback on the procedure and on specific aspects related to the preparation regime.
Following the procedure a telephone follow-up will be conducted at 48 hours (± 48 hours) post Pure-Vu procedure to assess patient well-being and capture any adverse events.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Tel Hashomer, Israel, 5265601
- Chaim Sheba Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subjects with history of inadequate bowel preparation.
- Subjects in the age range of 22-75 years inclusive
- Subjects with BodyMass Index (BMI) within the range of 18.5-35 inclusive
- Subject has signed the informed consent
Exclusion Criteria:
- Patients with active Inflammatory Bowel Disease
- Patients with previous history of acute diverticulitis disease or with prior incomplete colonoscopy due to diverticular disease
- Patients with known bowel obstruction / strictures
- History of prior surgery to colon and/or rectum
- ASA ≥ III
- Renal insufficiency (Creatinine ≥ 1.5mg /dL) (based on medical history)
- Abnormal Liver enzymes (ALT/AST ≥ 2 times upper limits of normal) (based on medical history)
- Patients taking anticoagulants drugs (excluding aspirin) or dual antiplatelet therapy
- Patients with known coagulation disorder (INR >1.5).
- Patients at risk of hypokalemia or hyponatremia
- Patients with congestive cardiac failure
- Pregnancy (as stated by patient) or breast feeding
- Patients with altered mental status/inability to provide informed consent
- Patients who have participated in another interventional clinical study in the last 2 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Motus Pure-Vu System
The Pure-Vu System enables colon cleansing during standard colonoscopy using a standard colonoscope.
The cleansing device, which is attached to the tip of the colonoscope and is connected to an external workstation, generates fluid jets within the colon thus dissolving the feces into small parts.
The fecal matter & fluids are drained through the evacuation pipe of the cleansing device into a collecting reservoir.
|
Pure-Vu System is intended to connect to standard colonoscopes to help facilitate intra-procedural cleaning of a poorly prepared colon by irrigating and/or cleaning the colon and evacuating the irrigation fluid (saline water), feces and other bodily fluids and matter, e.g.
blood.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Boston Bowel Preparation Scale( BBPS) >1 in All Colon Segments After the Use of Pure-Vu System
Time Frame: Up to 2 hours
|
The rating of the cleansing quality was evaluated by using the Boston Bowel Preparation Scale (BBPS), Segment score of 0-3 given to each of the 3 segments of the colon (Left side, Transverse and right side): Score 0- Unprepared colon segment with mucosa not seen due to solid stool that cannot be cleared. Score 1- A portion of the mucosa of the colon segment is seen, but other areas of the colon segment are not seen well due to staining, residual stool, and/or opaque liquid. Score 2- A minor amount of residual staining, small fragments of stool, and/or opaque liquid are visible, but the mucosa of the colon segment are seen well. Score 3-The entire mucosa of the colon segment is seen well with no residual staining, small fragments of stool, or opaque liquid. subject consider as having adequate cleaning if BBPS>1 in all colon segments |
Up to 2 hours
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- CL00046
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on CRC
-
Chinese University of Hong KongWithdrawn
-
Motus GI Medical Technologies LtdCompleted
-
Motus GI Medical Technologies LtdCompleted
-
Shanghai Henlius BiotechNot yet recruiting
-
Motus GI Medical Technologies LtdCompleted
-
Motus GI Medical Technologies LtdCompleted
-
The Netherlands Cancer InstituteErasmus Medical Center; Amsterdam University Medical Centres (AUMC)Active, not recruitingCRC | Advanced NeoplasiaNetherlands
-
Jacobio Pharmaceuticals Co., Ltd.RecruitingNSCLC | Solid Tumor | CRCChina
-
jianming xuKAEDIRecruiting
-
SparX Biotech(Jiangsu) Co., Ltd.RecruitingSolid Tumor | CRC | HNSCC | RCCUnited States
Clinical Trials on Pure-Vu System
-
Motus GI Medical Technologies LtdRecruiting
-
Radboud University Medical CenterMotus GI Medical Technologies Ltd; University Medical Center MainzCompletedColorectal Cancer | Bowel Preparation | Colonic AdenomaGermany, Netherlands
-
Motus GI Medical Technologies LtdCompletedColorectal Cancer | Gastrointestinal DiseaseUnited States
-
Motus GI Medical Technologies LtdWithdrawnColorectal Cancer | Gastrointestinal DiseaseUnited States
-
The Cleveland ClinicMotus GI Medical Technologies LtdTerminatedLower Gastrointestinal Bleeding | Hemostatic DisorderUnited States
-
Motus GI Medical Technologies LtdWithdrawnGastrointestinal Diseases | Colorectal Cancer
-
Children's Hospital Medical Center, CincinnatiRecruitingCardiac Anomaly | Pectus ExcavatumUnited States
-
Hospital General Universitario Gregorio MarañonCompletedBronchial Hyperreactivity | Inhalant UseSpain
-
Andrews Research & Education FoundationEmCyte Corporation; BioSciences Research Associates, IncCompletedKnee OsteoarthritisUnited States
-
National Taiwan University HospitalNational Science and Technology Council, TaiwanNot yet recruitingChronic StrokeTaiwan